Skip to main content
. 2019 May 7;127(5):057001. doi: 10.1289/EHP3325

Table 3.

Estimated effects of a 3-ppb increase in ozone (O3) exposure on IMTCCA progression and CP formation over 10 y, according to baseline participant characteristics.

n Change of IMTCCA (μm/10y) Odds ratio of CP formation
95% CI Interaction p-valuea 95% CI Interaction p-valuea
Sex 0.99 0.69
 Female 1,800 5.6 (0.3, 11.0) 1.3 (1.1, 1.5)
 Male 1,592 5.6 (0.3, 11.5) 1.2 (1.0, 1.4)
Race 0.99 0.09
 White 1,334 5.9 (0.8, 11.0) 1.4 (1.2, 1.6)
 Nonwhite 2,058 5.9 (0.7, 12.4) 1.1 (0.9, 1.3)
Age at baseline 0.25 0.58
<60y 1,658 3.5 (2.1, 9.0) 1.3 (1.1, 1.5)
60y 1,734 7.8 (2.2, 13.4) 1.4 (1.2, 1.6)
Smoking 0.36 0.09
 Never 1,658 3.9 (1.7, 9.5) 1.4 (1.2, 1.6)
 Former and current 1,729 7.4 (1.6, 13.1) 1.1 (1.0, 1.3)
Diabetes 0.05 0.11
 No 3,067 6.5 (2.1, 10.8) 1.2 (1.1, 1.3)
 Yes 325 4.5 (21.8, 12.8) 1.6 (1.2, 2.3)
Hypertension 0.91 0.30
 No 1,996 5.4 (0.1, 10.7) 1.1 (1.0, 1.3)
 Yes 1,396 5.9 (0.0, 11.7) 1.4 (1.2, 1.6)
Statin use 0.87 0.19
 No 2,880 5.9 (0.3, 11.4) 1.2 (1.1, 1.4)
 Yes 511 5.3 (0.0, 10.6) 1.3 (1.1, 1.5)
Presence of carotid plaqueb 0.04 0.79
 No 1,792 7.9 (2.1, 13.7) 1.2 (1.1, 1.4)
 Yes 1,600 0.5 (5.4, 6.3) 1.3 (1.1, 1.5)

Models included age, sex, race/ethnicity, study region, body mass index, smoking status, pack-years, secondhand smoke exposure, alcohol consumption, physical activity, employment status, high-density lipoprotein cholesterol, total cholesterol, statin use, neighborhood socioeconomic status (SES) index, income, education, systolic and diastolic blood pressure, hypertension, antihypertensive medication, and diabetes. Interquartile range (IQR) for within-city O3  exposure=3  ppb. Note: —, no data; CI, confidence interval; CP, carotid plaque; IMTCCA, intima-media thickness of common carotid artery.

a

p-Value by the F test of the three-way interaction between O3, study time, and stratification variable.

b

Presence of carotid plaque at baseline. Subset with no presence of carotid plaque indicate incidence of carotid plaque during follow-up.